Physician profile
Tricia E Hall
NPI 1962714022
$2,085.26
in general payments reported to CMS, 2019-2025
26 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $18.49 · 2021: $114 · 2022: $124 · 2023: $213 · 2024: $362 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.92 | 2022-2025 | |
| Lilly USA, LLC | $224.21 | 2021-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $197.65 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $95.13 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.72 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $88.12 | 2024-2025 | Veozah |
| Actelion Pharmaceuticals US, INC. | $80.61 | 2024-2025 | Opsumit, Uptravi |
| Scilex Pharmaceuticals INC. | $74.14 | 2019 | |
| Vanda Pharmaceuticals INC. | $64.12 | 2025 | Fanapt |
| Dexcom, INC. | $63.63 | 2023 | Dexcom G7 Gss (161) |
| Janssen Pharmaceuticals, INC | $60.90 | 2025 | Spravato |
| Amarin Pharma, INC. | $54.65 | 2021 | |
| Novo Nordisk INC | $42.46 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $38.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.53 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.49 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $30.76 | 2025 | Zoryve |
| Axsome Therapeutics, INC. | $26.48 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $24.80 | 2024 | Gemtesa |
| Ani Pharmaceuticals, INC. | $24.65 | 2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $20.51 | 2025 | |
| Genzyme Corporation | $20.49 | 2019 | |
| Horizon Therapeutics Plc | $18.49 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.73 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $15.95 | 2019 | |
| Strongbridge US INC. | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tricia Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.